Pharming Group Set to Engage Investors at Major Conference
Pharming Group's Upcoming Participation in an Investor Conference
Pharming Group N.V. recently announced its engagement in a significant investor conference scheduled for March. The excitement surrounding this engagement reflects the company's ongoing commitment to connect with investors and discuss their innovative approaches in the biopharmaceutical sector.
Details of the Investor Conference
The highlight of Pharming's participation will be at the 37th Annual Roth Conference, which is set to take place in Dana Point, CA. This prestigious event occurs from March 16 to March 18, 2025. Notably, Anurag Relan, Chief Medical Officer, and Michael Levitan, Vice President of Investor Relations and Corporate Communications, will lead the conversation during a fireside chat. This interactive session is slated for March 17 at 1:30 PM PT/9:30 PM CET, providing a valuable opportunity for attendees to learn more about Pharming's initiatives.
Connecting with Pharming's Management Team
Investors interested in a deeper dialogue with the management team can arrange one-on-one meetings during the conference. For additional details about the conference or to schedule a personal meeting, attendees are encouraged to reach out to Pharming's Investor Relations team directly at investor@pharming.com.
About Pharming Group N.V.
Pharming Group N.V. (NASDAQ: PHAR) is a leading global biopharmaceutical company committed to enriching the lives of patients suffering from rare and severe diseases. The company's mission revolves around the development and commercialization of a unique portfolio of protein replacement therapies and precision medicines. The extensive reach of Pharming's operations spans over 30 markets, including regions in North America, Europe, the Middle East, Africa, and Asia-Pacific.
Innovative Therapies by Pharming
The innovative therapies that Pharming is bringing to the forefront promise transformative effects for patients with complex health issues. By harnessing advanced protein replacement technology, Pharming aims to provide effective solutions for conditions that currently have limited treatment options. The development pipelines are robust, showcasing their dedication to research and development in the biopharmaceutical landscape.
Company Headquarters and Global Reach
Headquartered in Leiden, the Netherlands, Pharming Group employs a diverse workforce dedicated to serving patients around the globe. The company’s emphasis on biopharmaceutical research not only represents their commitment to patient care but also highlights their role in advancing the treatment paradigms in rare diseases.
Contact Information for Inquiries
For further inquiries regarding Pharming, interested parties can contact Michael Levitan, VP of Investor Relations and Corporate Communications, at +1 (908) 705 1696 or through investor@pharming.com. Furthermore, for general public relations, FTI Consulting in London can also be contacted at +44 203 727 1000.
Frequently Asked Questions
What is the purpose of the investor conference Phar is attending?
The investor conference is an opportunity for Pharming Group to engage with investors, discuss their latest innovations, and foster relationships within the biopharmaceutical community.
Who will represent Pharming at the conference?
Anurag Relan, Chief Medical Officer, and Michael Levitan, VP of Investor Relations and Corporate Communications, will represent Pharming at the conference.
When is the conference happening?
The 37th Annual Roth Conference occurs from March 16-18, 2025, with Pharming's presentation scheduled for March 17.
How can investors meet with Pharming's management?
Investors can arrange one-on-one meetings by contacting Pharming's Investor Relations team via email at investor@pharming.com.
What is Pharming's primary focus?
Pharming focuses on developing innovative protein replacement therapies and precision medicines for patients suffering from rare and severe diseases.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
